NAME : Tim Sreynith

SEX : Female

Aciclovir Oral Suspension

(2% = 200 mg/10 ml)

1. Formulation

Aciclovir ..............................................2.0 g

Kollidon CL-M [1] ................................6.0 g

Kollidon 30 [1] .....................................3.0 g

Sorbitol [10] ...........................................28.0 g

Citric acid ...........................................0.5 g

Preservative ...............................................q.s.

Water .....................................................60.5 g

2. Manufacturing

Suspend aciclovir and Kollidon CL-M in the solution of the

other compo- nents under vigorous stirring.

3. Properties of the solution

 Colour ................................................white Relative

sediment volume after 14 days ......96 %

Redispersibility after 14 days......................easy

4. Remarks

The substitution of Kollidon 30 by Kollidon 90F gives a

more compact sediment.

The deletion of citric acid gives a much more compact

sediment.

The substitution of citric acid by sodium citrate impairs

strongly the redispersibility.

Reference: BASF Pharma Ingredients Generic Drug Formulations 2004